

DAFTAR PUSTAKA

- Aapro, M., Crawford, J., Kamioner, D., 2010. Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now? *Support. Care Cancer Off. J. Multinat. Assoc. Support. Care Cancer* 18, 529–541. doi:10.1007/s00520-010-0816-y
- Aapro, M.S., Bohlius, J., Cameron, D.A., Dal Lago, L., Donnelly, J.P., Kearney, N., Lyman, G.H., Pettengell, R., Tjan-Heijnen, V.C., Walewski, J., Weber, D.C., Zielinski, C., European Organisation for Research and Treatment of Cancer, 2011. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. *Eur. J. Cancer Oxf. Engl.* 1990 47, 8–32. doi:10.1016/j.ejca.2010.10.013
- Anonim, 2013. NEUPOGEN® (filgrastim).
- Anonim, 2012. *Guidance on determining the absolute Neutrophil Count*. Dana Farbes/Harvard Cancer Center.
- Anonim, 2004. *Non Hodgkins Lymphoma Treatment Guidelines For Patient*. NCCN, ACSO.
- Astuti, L., Meiyanto, E., 2004. Evaluasi penggunaan Granulocyte Colony Stimulating Factor pada pasien kanker limfoma setelah pemberian kemoterapi di RS Kanker Dharmas Jakarta periode Januari 2001-September 2003. . *Thesis*. Universitas Gadjah Mada.
- Bakta, I.M., 2006. *Hematologi Klinik Ringkas*. Buku Kedokteran: EGC, Jakarta.
- Bolis, S., Cocorocchio, E., Corti, C., Ferreri, M.J., Grillo, G., Omodeo, E.S., Tedeschi, L., Zillioli, V.R., 2013. Clinical implications, Safety, Efficacy of Recombinant Granulocyte –Colony Stimulating Factors and Pegylated Equivalen. *Epidemiol. Biostat Public Health* 10, 4.
- Boxer, L.A., 2012. How to approach neutropenia. *Hematol. Educ. Program Am. Soc. Hematol. Am. Soc. Hematol. Educ. Program* 2012, 174–182. doi:10.1182/asheducation-2012.1.174
- Boxer, L., Dale, D.C., 2002. Neutropenia: Causes and consequences. *Semin. Hematol.* 39, 75–81. doi:10.1053/shem.2002.31911
- Carr, J., 2012. *Guideline for the Use of Granulocyte-Colony Stimulating Factor (G-CSF) in Adult Patients*. NHS.

- Carstensen, M., Sørensen, J.B., 2008. Outpatient management of febrile neutropenia: time to revise the present treatment strategy. *J. Support. Oncol.* 6, 199–208.
- Chan, A., Leng, X.Z., Chiang, J.Y.L., Tao, M., Quek, R., Tay, K., Lim, S.T., 2011. Comparison of daily filgrastim and pegfilgrastim to prevent febrile neutropenia in Asian lymphoma patients. *Asia Pac. J. Clin. Oncol.* 7, 75–81. doi:10.1111/j.1743-7563.2010.01355.x
- Chand, V.K., Link, B.K., Ritchie, J.M., Shannon, M., Wooldridge, J.E., 2006. Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy. *Leuk. Lymphoma* 47, 657–663. doi:10.1080/10428190500353430
- Choi, Y.W., Jeong, S.H., Ahn, M.S., Lee, H.W., Kang, S.Y., Choi, J.-H., Jin, U.R., Park, J.S., 2014. Patterns of Neutropenia and Risk Factors for Febrile Neutropenia of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP. *J. Korean Med. Sci.* 29, 1493–1500. doi:10.3346/jkms.2014.29.11.1493
- Cooper, K.L., Madan, J., Whyte, S., Stevenson, M.D., Akehurst, R.L., 2011. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. *BMC Cancer* 11, 404. doi:10.1186/1471-2407-11-404
- Crawford, J., Caserta, C., Roila, F., 2010. Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. *Ann. Oncol.* 21, v248–v251. doi:10.1093/annonc/mdq195
- Crawford, J., Dale, D.C., Lyman, G.H., 2004. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. *Cancer* 100, 228–237. doi:10.1002/cncr.11882
- Eichenauer, D.A., Engert, A., Andre, M., Federico, M., Illidge, T., Hutchings, M., Ladetto, M., on behalf of the ESMO Guidelines Working Group, 2014. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann. Oncol.* 25, iii70–iii75. doi:10.1093/annonc/mdu181
- Fiegl, M., Steger, G.G., Studnicka, M., Eisterer, W., Jaeger, C., Willenbacher, W., 2013. Pegfilgrastim prophylaxis in patients at different levels of risk for chemotherapy-associated febrile neutropenia: an observational study. *Curr. Med. Res. Opin.* 29, 505–515. doi:10.1185/03007995.2013.781018

- Gardellini, A., Gigli, F., Babic, A., Andreola, G., Radice, D., Sammassimo, S., Martinelli, G., Laszlo, D., 2013. Filgrastim XM02 (Tevagrastim®) after autologous stem cell transplantation compared to lenograstim: favourable cost-efficacy analysis. *ecancermedicalscience* 7. doi: 10.3332 / ecancer.2013.327
- Green, M.D., Koelbl, H., Baselga, J., Galid, A., Guillem, V., Gascon, P., Siena, S., Lalisang, R.I., Samonigg, H., Clemens, M.R., Zani, V., Liang, B.C., Renwick, J., Piccart, M.J., 2003. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. *Ann. Oncol.* 14, 29–35. doi:10.1093/annonc/mdg019
- Goodman, C.C., Fuller, K.S., 2015. *Pathology: Implications for the Physical Therapist*, 4e, 4 edition. ed. Saunders.
- Hakim, L., 2012. Farmakokinetik Klinik, Farmasi Klinik. *Bursa Ilmu*, Yogyakarta.
- Haustein, R., 2012. Saving money in the European healthcare systems with biosimilars. *Generics Biosimilars Initiat. J.* 1, 120–126. doi:10.5639/gabij.2012.0103-4.036
- Holmes, F.A., Jones, S.E., O’Shaughnessy, J., Vukelja, S., George, T., Savin, M., Richards, D., Glaspy, J., Meza, L., Cohen, G., Dhimi, M., Budman, D.R., Hackett, J., Brassard, M., Yang, B.B., Liang, B.C., 2002. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. *Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. ESMO* 13, 903–909.
- Hosmer, D.W., Hosmer, T., S., Lemeshow, S., 1997. A Comparison of Goodness-of-Fit Tests for the Logistic Regression Model. *Stat. Med.* 16, 965–980. doi:10.1002/(SICI)1097-0258(19970515)16:9<965::AID-SIM509>3.0.CO;2-O
- Intragumtornchai, T., Sutheesophon, J., Sutcharitchan, P., Swasdikul, D., 2000. A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin’s lymphoma. *Leuk. Lymphoma* 37, 351–360. doi:10.3109/10428190009089435
- Isidoro, M., Domingos, V., Gouveia, A.M., 2013. CPC-034 Comparison of Effectiveness and Safety of Primary Prophylaxis with Biosimilar Filgrastim Vs Reference Medicinal Product in Patients Treated with R-CHOP. *Eur. J. Hosp. Pharm. Sci. Pract.* 20, A177–A177. doi:10.1136/ejhpharm-2013-000276.491

- Lacy, C.F., Armstrong, L.L., Goldman, M., Lance, L., 2002. *Drug Information Handbook of Oncology*. Lexi-comp&AphA, Ohio,.
- Lalami, Y., Paesmans, M., Muanza, F., Barette, M., Plehiers, B., Dubreucq, L., Georgala, A., Klastersky, J., 2006. Can we predict the duration of chemotherapy-induced neutropenia in febrile neutropenic patients, focusing on regimen-specific risk factors? A retrospective analysis. *Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. ESMO* 17, 507–514. doi:10.1093/annonc/mdj092
- Lefrère, F., Brignier, A.-C., Elie, C., Ribeil, J.-A., Bernimoulin, M., Aoun, C., Dal Cortivo, L., Delarue, R., Hermine, O., Cavazzana-Calvo, M., 2011. First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony-stimulating factor. *Adv. Ther.* 28, 304–310. doi:10.1007/s12325-011-0009-1
- Lyman, G.H., Abella, E., Pettengell, R., 2014. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review. *Crit. Rev. Oncol. Hematol.* 90, 190–199. doi:10.1016/j.critrevonc.2013.12.006
- Lyman, G.H., Delgado, D.J., 2003. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. *Cancer* 98, 2402–2409. doi:10.1002/cncr.11827
- Lyman, G.H., Kuderer, N.M., Crawford, J., Wolff, D.A., Culakova, E., Poniewierski, M.S., Dale, D.C., 2011. Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. *Cancer* 117, 1917–1927. doi:10.1002/cncr.25691
- Lyman, G.H., Kuderer, N.M., Crawford, J., Wolff, D.A., Culakova, E., Poniewierski, M.S., Dale, D.C. for the ANC Study Group, 2006. Prospective validation of a risk model for first cycle neutropenic complications in patients receiving cancer chemotherapy. *ASCO Meet. Abstr.* 24, 8561.
- Lyman, G.H., Morrison, V.A., Dale, D.C., Crawford, J., Delgado, D.J., Fridman, M., OPPS Working Group, ANC Study Group, 2003. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. *Leuk. Lymphoma* 44, 2069–2076.

- Nademanee, A., Sniecinski, I., Schmidt, G.M., Dagis, A.C., O'Donnell, M.R., Snyder, D.S., Parker, P.M., Stein, A.S., Smith, E.P., Molina, A., 1994. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* 12, 2176–2186.
- Naurois, J. de, Novitzky-Basso, I., Gill, M.J., Marti, F.M., Cullen, M.H., Roila, F., 2010. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. *Ann. Oncol.* 21, v252–v256. doi:10.1093/annonc/mdq196
- Orciuolo, E., Buda, G., Marturano, E., Mauro, E., Milone, G., Cangialosi, C., Di Renzo, N., Pastore, D., Specchia, G., De Paolis, M.R., Mazza, P., Pietrantuono, G., Petrini, M., 2011. Lenograstim reduces the incidence of febrile episodes, when compared with filgrastim, in multiple myeloma patients undergoing stem cell mobilization. *Leuk. Res.* 35, 899–903. doi:10.1016/j.leukres.2010.10.029
- Pérez Velasco, R., 2011. Review of granulocyte colony-stimulating factors in the treatment of established febrile neutropenia. *J. Oncol. Pharm. Pract. Off. Publ. Int. Soc. Oncol. Pharm. Pract.* 17, 225–232. doi:10.1177/1078155210374129
- Peterson, G.M., 2011. Generic substitution: a need for clarification. *Br. J. Clin. Pharmacol.* 71, 966–967. doi:10.1111/j.1365-2125.2010.03872.x
- Pettengell, R., Bosly, A., Szucs, T.D., Jackisch, C., Leonard, R., Paridaens, R., Constenla, M., Schwenkglenks, M., 2008. Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study. *Br. J. Haematol.* 144, 677–685. doi:10.1111/j.1365-2141.2008.07514.x
- Pettengell, R., Bosly, A., Szucs, T.D., Jackisch, C., Leonard, R., Paridaens, R., Constenla, M., Schwenkglenks, M., for the Impact of Neutropenia in Chemotherapy - European Study Group (INC-EU), 2009. Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study. *Br. J. Haematol.* 144, 677–685. doi:10.1111/j.1365-2141.2008.07514.x
- Rathore, A., 2011. Quality by design for biologics and biosimilars AS Rathore. *Pharm. Technol.* 35, 64–68.
- Rosary, Sjakti, H.A., 2010. Penggunaan Granulocyte Colony-Stimulating Factor pada Pasien Tumor Padat yang Mengalami Neutropenia. *Sari Pediatri* 11.

- Sampurno, 2011. *Manajemen Pemasaran Farmasi*. Gadjah Mada University Press, Yogyakarta.
- Schippinger, W., Holub, R., Dandachi, N., Bauernhofer, T., Samonigg, H., 2006. Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim. *Oncology* 70, 290–293. doi:10.1159/000094890
- Sevinc, A., Ozkan, M., Ozet, A., Dane, F., Oksuzoglu, B., Isikdogan, A., Ozdemir, F., Uncu, D., Gumus, M., Evrensel, T., Yaren, A., Kara, O., Tekin, S.B., 2014. Comparison of the Efficacy of Filgrastim (neupogen®) and Biosimilar Filgrastim (leucostim®) in Patients with Chemotherapy-Induced Neutropenia: A Nationwide Observational Study. *Ann. Oncol.* 25, iv525–iv525. doi:10.1093/annonc/mdu356.22
- Shah, P., Misra, A., Gupta, N., Hazra, D.K., Gupta, R., Seth, P., Agarwal, A., Gupta, A.K., Jain, A., Kulshrestha, A., Hazra, N., Khanna, P., Gangwar, P.K., Bansal, S., Tallikoti, P., Mohan, I., Bhargava, R., Sharma, R., Gulati, S., Bharadwaj, S., Pandey, R.M., Goel, K., 2010. Improvement in nutrition-related knowledge and behaviour of urban Asian Indian school children: findings from the “Medical education for children/Adolescents for Realistic prevention of obesity and diabetes and for healthy ageing” (MARG) intervention study. *Br. J. Nutr.* 104, 427–436. doi:10.1017/S0007114510000681
- Shargel, L., Yu, A., Wu-Pong, S., 2012. *Applied Biopharmaceutics & Pharmacokinetics*, Sixth Edition, 6 edition. ed. McGraw-Hill Medical, New York.
- Shayne, M., Culakova, E., Poniewierski, M.S., Wolff, D., Dale, D.C., Crawford, J., Lyman, G.H., 2007. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. *Cancer* 110, 1611–1620. doi:10.1002/cncr.22939
- Silvestris, N., Del Re, M., Azzariti, A., Maiello, E., Lombardi, L., Cinieri, S., Guarini, A., Brunetti, A.E., Delcuratolo, S., De Vita, F., Pisconti, S., Danesi, R., Colucci, G., 2012. Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines. *Expert Opin. Ther. Targets* 16 Suppl 2, S111–117. doi:10.1517/14728222.2011.652089
- Smith, T.J., Khatcheressian, J., Lyman, G.H., Ozer, H., Armitage, J.O., Balducci, L., Bennett, C.L., Cantor, S.B., Crawford, J., Cross, S.J., Demetri, G., Desch, C.E., Pizzo, P.A., Schiffer, C.A., Schwartzberg, L., Somerfield, M.R., Somlo, G., Wade, J.C., Wade, J.L., Winn, R.J., Wozniak, A.J.,

- Wolff, A.C., 2006. 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline. *J. Clin. Oncol.* 24, 3187–3205. doi:10.1200/JCO.2006.06.4451
- Sörgel, F., Schwebig, A., Holzmann, J., Prasch, S., Singh, P., Kinzig, M., 2015. Comparability of biosimilar filgrastim with originator filgrastim: protein characterization, pharmacodynamics, and pharmacokinetics. *BioDrugs Clin. Immunother. Biopharm. Gene Ther.* 29, 123–131. doi:10.1007/s40259-015-0124-7
- Vanstraelen, G., Frère, P., Ngirabacu, M.-C., Willems, E., Fillet, G., Beguin, Y., 2006. Pegfilgrastim compared with Filgrastim after autologous hematopoietic peripheral blood stem cell transplantation. *Exp. Hematol.* 34, 382–388. doi:10.1016/j.exphem.2005.11.013
- Voog, E., Bienvenu, J., Warzocha, K., Moullet, I., Dumontet, C., Thieblemont, C., Monneret, G., Gutowski, M.-C., Coiffier, B., Salles, G., 2000. Factors That Predict Chemotherapy-Induced Myelosuppression in Lymphoma Patients: Role of the Tumor Necrosis Factor Ligand-Receptor System. *J. Clin. Oncol.* 18, 325–325.
- Waller, C.F., Bronchud, M., Mair, S., Challand, R., 2010a. Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial. *Ann. Hematol.* 89, 971–978. doi:10.1007/s00277-010-0973-6
- Whyte, S., Cooper, K.L., Stevenson, M.D., Madan, J., Akehurst, R., 2011. Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the United Kingdom. *Value Health J. Int. Soc. Pharmacoeconomics Outcomes Res.* 14, 465–474. doi:10.1016/j.jval.2010.10.037
- Wilson-Royal, M., Lawless, G., Palmer, C., Brown, R., 2001. Predictors for chemotherapy-related severe or febrile neutropenia: a review of the clinical literature. *J. Oncol. Pharm. Pract.* 7, 141–147. doi:10.1191/1078155201jp084oa